Moneycontrol PRO
you are here: HomeNewsSun pharma
sun pharma
Jump to
1209 Results Found
  • Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US, Canada Aug 31, 2021 02:48 PM IST

    Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US, Canada

    Sun Pharma now has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021, it added.

  • Sun Pharma Consolidated June 2021 Net Sales at Rs 9,718.74 crore, up 28.13% Y-o-Y Aug 03, 2021 09:22 AM IST

    Sun Pharma Consolidated June 2021 Net Sales at Rs 9,718.74 crore, up 28.13% Y-o-Y

  • Sun Pharma Standalone June 2021 Net Sales at Rs 3,325.95 crore, up 12.25% Y-o-Y Aug 03, 2021 08:44 AM IST

    Sun Pharma Standalone June 2021 Net Sales at Rs 3,325.95 crore, up 12.25% Y-o-Y

  • Sun Pharma: Ilumya illuminates Aug 02, 2021 10:13 AM IST

    Sun Pharma: Ilumya illuminates

    The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms

  • un Pharma Q1 PAT seen up 23.7% YoY to Rs 1,417.3 cr: ICICI Direct Jul 12, 2021 07:56 PM IST

    un Pharma Q1 PAT seen up 23.7% YoY to Rs 1,417.3 cr: ICICI Direct

    Net Sales are expected to increase by 19.5 percent Y-o-Y (up 6.3 percent Q-o-Q) to Rs 9062.7 crore, according to ICICI Direct.

  • How Erez Israeli revived Dr Reddy’s by focusing on costs and non-US markets Jul 08, 2021 09:17 AM IST

    How Erez Israeli revived Dr Reddy’s by focusing on costs and non-US markets

    Erez Israeli who took over as chief executive officer of DRL in 2019 sharpened its focus on costs and execution. Its recovery holds a lesson or two for major drug firms

  • No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma Jun 13, 2021 01:17 PM IST

    No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma

    The Mumbai-based company, which is strong in various generic therapeutic segments, is eyeing biosimilars to fuel its future growth.

  • Hold Sun Pharma; target of Rs 720: Emkay Global Financial May 31, 2021 05:38 PM IST

    Hold Sun Pharma; target of Rs 720: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 720 in its research report dated May 28, 2021.

  • Buy Sun Pharma; target of Rs 830: Motilal Oswal May 31, 2021 12:35 PM IST

    Buy Sun Pharma; target of Rs 830: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 830 in its research report dated May 28, 2021.

  • Sun Pharma: Traction in speciality likely to sustain May 31, 2021 10:53 AM IST

    Sun Pharma: Traction in speciality likely to sustain

    Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

  • Sun Pharma Consolidated March 2021 Net Sales at Rs 8,522.98 crore, up 4.13% Y-o-Y May 28, 2021 02:25 PM IST

    Sun Pharma Consolidated March 2021 Net Sales at Rs 8,522.98 crore, up 4.13% Y-o-Y

  • Sun Pharma Standalone March 2021 Net Sales at Rs 3,159.64 crore, up 11.41% Y-o-Y May 28, 2021 02:00 PM IST

    Sun Pharma Standalone March 2021 Net Sales at Rs 3,159.64 crore, up 11.41% Y-o-Y

  • Dilip Shanghvi resigns as MD of SPARC May 26, 2021 08:32 AM IST

    Dilip Shanghvi resigns as MD of SPARC

    Shanghvi will, however, continue to be associated with the company's board in his capacity as a non-executive director and chairman, it added.

  • Sun Pharma share price hits new 52-week high after getting licence to produce low-cost COVID-19 drug May 11, 2021 10:03 AM IST

    Sun Pharma share price hits new 52-week high after getting licence to produce low-cost COVID-19 drug

    US drugmaker Eli Lilly and Co. said it has issued royalty-free, non-exclusive voluntary licences to Sun Pharmaceutical Industries to produce its baricitinib drug in India to help combat the second wave of COVID-19 in India.

  • Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan

    Net Sales are expected to increase by 6.2 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 8,692.6 crore, according to Sharekhan.

  • Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market Mar 14, 2021 11:29 AM IST

    Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market

    As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Sun Pharma is recalling Cequa ophthalmic solution, which is used to treat chronic dry eye.

  • Aditya Medisales case | Sun Pharma founder Dilip Shanghvi ordered to pay Rs 62.35 lakh for settling whistle-blower charges Feb 11, 2021 05:35 PM IST

    Aditya Medisales case | Sun Pharma founder Dilip Shanghvi ordered to pay Rs 62.35 lakh for settling whistle-blower charges

    The whistle-blower alleged that Sun Pharma and its subsidiary, Sun Pharmaceutical Laboratories, had diverted funds through Aditya Medisales, its sole distributor in India.

  • Buy Sun Pharma; target of Rs 740: Motilal Oswal Feb 03, 2021 08:46 PM IST

    Buy Sun Pharma; target of Rs 740: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated January 30, 2021.

  • Sun Pharma Consolidated December 2020 Net Sales at Rs 8,836.78 crore, up 8.36% Y-o-Y Feb 02, 2021 09:55 AM IST

    Sun Pharma Consolidated December 2020 Net Sales at Rs 8,836.78 crore, up 8.36% Y-o-Y

  • Sun Pharma Standalone December 2020 Net Sales at Rs 3,388.02 crore, up 12.43% Y-o-Y Feb 02, 2021 09:11 AM IST

    Sun Pharma Standalone December 2020 Net Sales at Rs 3,388.02 crore, up 12.43% Y-o-Y

  • Pharma: Ignore the noise as the core allocation is incremental Feb 01, 2021 07:32 PM IST

    Pharma: Ignore the noise as the core allocation is incremental

    Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies

  • Sun Pharma: Sustained traction in speciality to be a re-rating driver Jan 31, 2021 12:42 PM IST

    Sun Pharma: Sustained traction in speciality to be a re-rating driver

    Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

  • Sun Pharma beats estimates in Q3 as profit doubles to Rs 1,852.5 crore Jan 29, 2021 02:29 PM IST

    Sun Pharma beats estimates in Q3 as profit doubles to Rs 1,852.5 crore

    The company announced an interim dividend of Rs 5.50 per share.

  • Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable Jan 29, 2021 07:33 AM IST

    Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable

    Brokerage firm Motilal Oswal Financial Services expects a 65.7 percent YoY rise in adjusted net profit and a 7.3 percent YoY rise in revenue for the quarter.

  • Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities Jan 22, 2021 01:03 PM IST

    Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities

    Net Sales are expected to increase by 7.7 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 8,782.1 crore, according to Yash Securities.

Sections
ISO 27001 - BSI Assurance Mark